Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104 - a randomized trial of the German AIO CRC Study

oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663–671. 3. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342. 4. Ocvirk J, Brodowicz T, Wrba F et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16: 3133–3143. 5. Moosmann N, Fischer von Weikersthal L, Vehling-Kaiser U et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104 a randomized trial of the German AIO CRC Study Group. J Clin Oncol 2011; 29 (8): 1050–1058. 6. Tveit K, Guren T, Glimelius B et al. Randomized phase III study of 5-fluorouracil/ folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII Study (NCT00145314). Ann Oncol 2010; 21Suppl 8(Abstr LBA20). 35th ESMO Conference 2010, Edition. Milan, Italy 7. Maughan T, Adams R, Smith C et al. The addition of cetuximab to oxaliplatinfluoropyrimidine chemotherapy in first-line advanced colorectal cancer in the MRC COIN trial: identification of potentially responsive subsets of patients. Ann Oncol 2010; 21: 17–18. 8. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779–4786. 9. Sobrero A, Ackland S, Clarke S et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in firstline metastatic colorectal cancer. Oncology 2009; 77: 113–119. 10. Lopez R, Salgado M, Reboredo M et al. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer 2010; 103: 1536–1541. 11. Hurwitz HI, Yi J, Ince W et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009; 14: 22–28. 12. Reinacher-Schick A, Schmiegel W Impact of KRAS status on survival in patients (pts.) with metastatic colorectal cancer (mCRC) undergoing bevacizumab (bev) containing chemotherapy regimen—analysis of the AIO Colorectal Cancer Study Group. Ann Oncol 201021 (Suppl 8) (Abstr 585PD) 13. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229–237. 14. Jung A, Baretton G, Dietel M et al. The German quality assurance system for the molecular-pathological detection of KRAS-mutations in colorectal cancer. J Clin Oncol 2009; 27Suppl15s. (Abstr 4018). 2009 ASCO Annual Meeting 15. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011–2019. 16. Stathopoulos GP, Batziou C, Trafalis D et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010; 78: 376–381. 17. De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812–1820. 18. Tejpar S, Bokemeyer C, Celik I et al. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with firstline chemotherapy with or without cetuximab. J Clin Oncol 201129 (Suppl) (Abstr 3511)